KB-1265

Utomilumab

52690

Home » Utomilumab

Background of Utomilumab

Utomilumab(PF-05082566), is a recombinant IgG2 lambda, humanized monoclonal antibody produced in CHO cell culture, which binds specifically to 4-1BB(CD137), a receptor protein found in many immune cells, such as T-cells and NK cells. And when Utomilumab binds to 4-1BB, it has been observed to stimulate and increase the number of immune cells.

Specifications

Catalog Number	KB-1265
Antibody Name	Utomilumab
Isotype	Human IgG2,lambda
FC Muations	WT
Target	CD137
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Ajay K. Gopal, Ronald Levy, Roch Houot, Sandip P. Patel, Leslie Popplewell, et al. First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas. Clin Cancer Res. CCR-19-2973 Published June 2020.